A 38-week , double-blind , active-controlled , non-inferiority study ; randomisation ( 2:2:1 ) to aripiprazole once-monthly 400 mg , oral aripiprazole ( 10-30 mg/day ) or aripiprazole once-monthly 50 mg ( a dose below the therapeutic threshold for assay sensitivity ) .